Ocugen Q3 2026 net loss narrows to $3.6 million on $16.6 million derivative gain
Ocugen reported third quarter 2026 results, with revenue rising to $1.951 million and net loss narrowing to $3.6 million from $20.1 million a year earlier. The narrower loss came mainly from a $16.6 million change in the fair value of a derivative liability, while operating loss widened slightly to $17.8 million, and cash and short-term investments totaled $84.6 million as of September 30, 2026.
Key points
- Collaborative arrangement revenue was $1.951 million, compared with $1.752 million in the third quarter of 2025.
- Total operating expenses were $19.7 million, up from $19.4 million, including $12.5 million in research and development.
- Net loss per share was $(0.01), compared with $(0.07) a year earlier; the filing says cash is expected to fund operations into 2028.
- Ocugen signed an exclusive OCU400 license for the Middle East and North Africa with Roots Pharmaceutical, with up to $4 million in upfront and initial development milestone payments and a 22% royalty on net sales.
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.